Warner Chilcott (US), LLC et al v. Teva Pharmaceuticals USA, Inc. et al, No. 2:15-cv-01471 (E.D. Tex. July 12, 2017)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

In these consolidated patent infringement lawsuits, Allergan Sales, LLC (“Allergan”) and Qualicaps Co., LTD. (“Qualicaps”) allege that Teva Pharmaceuticals USA, Inc. (“Teva”), Mylan Pharmaceuticals, Inc., Mylan Laboratories Limited, and Mylan, Inc. (collectively “Mylan”) are seeking FDA approval to market and sell a generic version of Allergan’ s branded Delzicol drug product in violation of U.S. Patent No. 6,649,180 (“the ’180 patent”). Before the court is the matter of claim construction.